REGENXBIO (DB:RB0) - Stock Price, News & Analysis

RB0 Stock Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

About the company

RB0 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 92.7% below our estimate of its fair value

Revenue is forecast to grow 40.83% per year

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

REGENXBIO Inc. Competitors

Formycon

XTRA:FYB

€701.1m

Biotest

XTRA:BIO3

€1.4b

MorphoSys

XTRA:MOR

€2.6b

Heidelberg Pharma

XTRA:HPHA

€141.2m

Price History & Performance

Summary of all time highs, changes and price drops for REGENXBIO
Historical stock prices
Current Share Price	US$14.80
52 Week High	US$23.60
52 Week Low	US$11.20
Beta	1.32
1 Month Change	-25.25%
3 Month Change	22.31%
1 Year Change	-10.84%
3 Year Change	-49.71%
5 Year Change	-65.75%
Change since IPO	-31.52%

Recent updates

Shareholder Returns

	RB0	DE Biotechs	DE Market
7D	-6.9%	-0.2%	0.5%
1Y	-10.8%	-22.8%	1.3%

Return vs Industry: RB0 exceeded the German Biotechs industry which returned -23% over the past year.

Return vs Market: RB0 underperformed the German Market which returned 2.3% over the past year.

Price Volatility

Is RB0's price volatile compared to industry and market?
RB0 volatility
RB0 Average Weekly Movement	13.2%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: RB0's share price has been volatile over the past 3 months.

Volatility Over Time: RB0's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2008	344	Ken Mills	www.regenxbio.com

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

REGENXBIO Inc. Fundamentals Summary

How do REGENXBIO's earnings and revenue compare to its market cap?
RB0 fundamental statistics
Market cap	€733.31m
Earnings (TTM)	-€245.63m
Revenue (TTM)	€84.12m

8.7x

P/S Ratio

-3.0x

P/E Ratio

Is RB0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RB0 income statement (TTM)
Revenue	US$90.24m
Cost of Revenue	US$266.48m
Gross Profit	-US$176.24m
Other Expenses	US$87.26m
Earnings	-US$263.49m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-5.37
Gross Margin	-195.29%
Net Profit Margin	-291.99%
Debt/Equity Ratio	30.2%

How did RB0 perform over the long term?

See historical performance and comparison

RB0 Stock Overview

Rewards

Risk Analysis

REGENXBIO Inc. Competitors

XTRA:FYB

€701.1m

XTRA:BIO3

€1.4b

XTRA:MOR

€2.6b

XTRA:HPHA

€141.2m

Price History & Performance

Recent News & Updates

REGENXBIO Inc., Annual General Meeting, May 31, 2024

REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial

New minor risk - Shareholder dilution

Recent updates

REGENXBIO Inc., Annual General Meeting, May 31, 2024

REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$6.03 loss per share (vs US$6.50 loss in FY 2022)

New major risk - Financial position

REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

New major risk - Financial position

REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$1.75 loss in 3Q 2022)

REGENXBIO Inc. Presents Positive One Year Data from Phase II ALTUDE®? Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

New minor risk - Share price stability

Vitreous Retina Macula Consultants of New York Announces Participation in Wet AMD Study in Collaboration with Regenxbio

REGENXBIO Inc. Announces Additional Interim Safety Data and Initial Efficacy Data from the Phase I/II AFFINITY Duchenne Trial of RGX-202

REGENXBIO Inc. Announces Initial Clinical Data from First Pediatric CLN2 Patient Dosed with RGX-181

Second quarter 2023 earnings released: US$1.66 loss per share (vs US$1.58 loss in 2Q 2022)

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

First quarter 2023 earnings released: US$1.54 loss per share (vs US$1.79 loss in 1Q 2022)

Full year 2022 earnings released: US$6.50 loss per share (vs US$3.01 profit in FY 2021)

REGENXBIO Inc. Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

REGENXBIO Inc. Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients

REGENXBIO Inc. Announces Executive Promotions

REGENXBIO Inc. Reports Update on Advancement of Programs for CLN2 Disease

Regenxbio Announces Completion of Dosing in the Phase I/Ii Trial of Rgx-111 for the Treatment of Severe Mps I

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: US$1.75 loss per share (vs US$1.37 loss in 3Q 2021)

REGENXBIO Inc. Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE(R) Trial of Rgx-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

Investor sentiment improved over the past week

Regenxbio Inc. Announces Additional Positive Interim Data from the Phase I/Ii/Iii Campsiite™ Trial of Rgx-121 for the Treatment of Patients Up to 5 Years Old Diagnosed with Mucopolysaccharidosis Type Ii (Mps Ii), Also Known as Hunter Syndrome

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: US$1.58 loss per share (vs US$1.36 loss in 2Q 2021)

REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II

Executive VP & Chief Financial Officer recently sold €144k worth of stock

Investor sentiment improved over the past week

REGENXBIO Inc. Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial

Investor sentiment improved over the past week

Regenxbio Inc. Appoints Jennifer Zachary to its Board of Directors

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: US$1.79 loss per share (vs US$1.20 loss in 1Q 2021)

REGENXBIO Inc., Annual General Meeting, Jun 03, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO Inc. Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

REGENXBIO Inc. Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery

REGENXBIO Inc. Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

REGENXBIO Inc. Announces Orphan Drug Designation Granted to RGX-202, A Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

Third quarter 2021 earnings released: US$1.37 loss per share (vs US$0.23 profit in 3Q 2020)

REGENXBIO Inc. Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting

Chairman of the Board recently sold €1.9m worth of stock

Independent Director Luke Beshar has left the company

Second quarter 2021 earnings released: US$1.36 loss per share (vs US$0.91 loss in 2Q 2020)

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting

First quarter 2021 earnings released: US$1.20 loss per share (vs US$1.08 loss in 1Q 2020)

Full year 2020 earnings released: US$2.98 loss per share (vs US$2.58 loss in FY 2019)

Revenue misses expectations

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD